APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulocyte Macrophage Colony Stimulating Factor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Granulocyte Macrophage Colony Stimulating Factor Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchGranulocyte Macrophage Colony Stimulating Factor Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocyte Macrophage Colony Stimulating Factor Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Granulocyte Macrophage Colony Stimulating Factor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocyte Macrophage Colony Stimulating Factor Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocyte Macrophage Colony Stimulating Factor Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Granulocyte Macrophage Colony Stimulating Factor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Granulocyte Macrophage Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulocyte Macrophage Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulocyte Macrophage Colony Stimulating Factor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Granulocyte Macrophage Colony Stimulating Factor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Granulocyte Macrophage Colony Stimulating Factor market include Takeda Pharmaceutical Co Ltd, GlaxoSmithKline Plc, Amgen Inc, Sillajen Biotherapeutics, Morphotek Inc, Mologen AG, Humanigen Inc, Cold Genesys Inc and BriaCell Therapeutics Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Granulocyte Macrophage Colony Stimulating Factor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulocyte Macrophage Colony Stimulating Factor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulocyte Macrophage Colony Stimulating Factor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Granulocyte Macrophage Colony Stimulating Factor market size, projected growth trends, production technologies, key applications, and end-use industries.

Granulocyte Macrophage Colony Stimulating Factor Segment by Company

Takeda Pharmaceutical Co Ltd

GlaxoSmithKline Plc

Amgen Inc

Sillajen Biotherapeutics

Morphotek Inc

Mologen AG

Humanigen Inc

Cold Genesys Inc

BriaCell Therapeutics Corp

Aduro BioTech Inc

Granulocyte Macrophage Colony Stimulating Factor Segment by Type

CG-0070

Lenzilumab

Gimsilumab

MGN-1601

GSK-3196165

Others

Granulocyte Macrophage Colony Stimulating Factor Segment by Application

Solid Tumor

Kidney Cancer

Lymphoma

Lung Disease

Others

Granulocyte Macrophage Colony Stimulating Factor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Granulocyte Macrophage Colony Stimulating Factor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Granulocyte Macrophage Colony Stimulating Factor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Granulocyte Macrophage Colony Stimulating Factor significant trends, drivers, influence factors in global and regions.

6. To analyze Granulocyte Macrophage Colony Stimulating Factor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte Macrophage Colony Stimulating Factor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocyte Macrophage Colony Stimulating Factor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte Macrophage Colony Stimulating Factor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Granulocyte Macrophage Colony Stimulating Factor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Granulocyte Macrophage Colony Stimulating Factor industry.

Chapter 3: Detailed analysis of Granulocyte Macrophage Colony Stimulating Factor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Granulocyte Macrophage Colony Stimulating Factor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Granulocyte Macrophage Colony Stimulating Factor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Granulocyte Macrophage Colony Stimulating Factor Industry Trends Table 2. Granulocyte Macrophage Colony Stimulating Factor Industry Drivers Table 3. Granulocyte Macrophage Colony Stimulating Factor Industry Opportunities and Challenges Table 4. Granulocyte Macrophage Colony Stimulating Factor Industry Restraints Table 5. Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Granulocyte Macrophage Colony Stimulating Factor Revenue Share by Company (2021-2026) Table 7. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Company (2021-2026) Table 9. Global Granulocyte Macrophage Colony Stimulating Factor Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Granulocyte Macrophage Colony Stimulating Factor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Granulocyte Macrophage Colony Stimulating Factor Key Company Manufacturing Base & Headquarters Table 12. Global Granulocyte Macrophage Colony Stimulating Factor Company, Product Type & Application Table 13. Global Granulocyte Macrophage Colony Stimulating Factor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Granulocyte Macrophage Colony Stimulating Factor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of CG-0070 Table 18. Significant Companies of Lenzilumab Table 19. Significant Companies of Gimsilumab Table 20. Significant Companies of MGN-1601 Table 21. Significant Companies of GSK-3196165 Table 22. Significant Companies of Others Table 23. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Type (2021-2026) Table 27. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Type (2027-2032) Table 28. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type (2021-2026) Table 32. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Solid Tumor Table 34. Significant Companies of Kidney Cancer Table 35. Significant Companies of Lymphoma Table 36. Significant Companies of Lung Disease Table 37. Significant Companies of Others Table 38. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Application (2021-2026) & (K Units) Table 40. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Application (2027-2032) & (K Units) Table 41. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Application (2021-2026) Table 42. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Application (2027-2032) Table 43. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Application (2021-2026) & (US$ Million) Table 45. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Application (2027-2032) & (US$ Million) Table 46. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application (2021-2026) Table 47. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application (2027-2032) Table 48. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 49. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region (2021-2026) & (K Units) Table 50. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Region (2021-2026) Table 51. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region (2027-2032) & (K Units) Table 52. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Region (2027-2032) Table 53. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 54. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Region (2021-2026) & (US$ Million) Table 55. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Region (2021-2026) Table 56. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Region (2027-2032) & (US$ Million) Table 57. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Region (2027-2032) Table 58. Global Granulocyte Macrophage Colony Stimulating Factor Market Average Price (US$/Unit) by Region (2021-2026) Table 59. Global Granulocyte Macrophage Colony Stimulating Factor Market Average Price (US$/Unit) by Region (2027-2032) Table 60. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 61. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2026) & (K Units) Table 63. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Country (2021-2026) Table 64. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2027-2032) & (K Units) Table 65. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Country (2027-2032) Table 66. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country (2021-2026) & (US$ Million) Table 67. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Market Share by Country (2021-2026) Table 68. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country (2027-2032) & (US$ Million) Table 69. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Market Share by Country (2027-2032) Table 70. Takeda Pharmaceutical Co Ltd Company Information Table 71. Takeda Pharmaceutical Co Ltd Business Overview Table 72. Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 74. Takeda Pharmaceutical Co Ltd Recent Development Table 75. GlaxoSmithKline Plc Company Information Table 76. GlaxoSmithKline Plc Business Overview Table 77. GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 79. GlaxoSmithKline Plc Recent Development Table 80. Amgen Inc Company Information Table 81. Amgen Inc Business Overview Table 82. Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 84. Amgen Inc Recent Development Table 85. Sillajen Biotherapeutics Company Information Table 86. Sillajen Biotherapeutics Business Overview Table 87. Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 89. Sillajen Biotherapeutics Recent Development Table 90. Morphotek Inc Company Information Table 91. Morphotek Inc Business Overview Table 92. Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 94. Morphotek Inc Recent Development Table 95. Mologen AG Company Information Table 96. Mologen AG Business Overview Table 97. Mologen AG Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Mologen AG Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 99. Mologen AG Recent Development Table 100. Humanigen Inc Company Information Table 101. Humanigen Inc Business Overview Table 102. Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 104. Humanigen Inc Recent Development Table 105. Cold Genesys Inc Company Information Table 106. Cold Genesys Inc Business Overview Table 107. Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 109. Cold Genesys Inc Recent Development Table 110. BriaCell Therapeutics Corp Company Information Table 111. BriaCell Therapeutics Corp Business Overview Table 112. BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 114. BriaCell Therapeutics Corp Recent Development Table 115. Aduro BioTech Inc Company Information Table 116. Aduro BioTech Inc Business Overview Table 117. Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio Table 119. Aduro BioTech Inc Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Granulocyte Macrophage Colony Stimulating Factor Distributors List Table 123. Granulocyte Macrophage Colony Stimulating Factor Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Granulocyte Macrophage Colony Stimulating Factor Product Image Figure 2. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Granulocyte Macrophage Colony Stimulating Factor Sales (2021-2032) & (K Units) Figure 5. Global Granulocyte Macrophage Colony Stimulating Factor Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Granulocyte Macrophage Colony Stimulating Factor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. CG-0070 Image Figure 10. Lenzilumab Image Figure 11. Gimsilumab Image Figure 12. MGN-1601 Image Figure 13. GSK-3196165 Image Figure 14. Others Image Figure 15. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Type (2021-2032) Figure 18. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type (2021-2032) Figure 21. Solid Tumor Image Figure 22. Kidney Cancer Image Figure 23. Lymphoma Image Figure 24. Lung Disease Image Figure 25. Others Image Figure 26. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share 2021 VS 2025 VS 2032 Figure 28. Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Application (2021-2032) Figure 29. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share 2021 VS 2025 VS 2032 Figure 31. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application (2021-2032) Figure 32. Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 33. Global Granulocyte Macrophage Colony Stimulating Factor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 34. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 35. Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 36. North America Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032) & (US$ Million) Figure 37. North America Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Europe Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032) & (US$ Million) Figure 39. Europe Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 42. South America Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032) & (US$ Million) Figure 43. South America Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032) & (US$ Million) Figure 45. Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country (%), 2025 VS 2032 Figure 46. USA Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. USA Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. USA Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Canada Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Canada Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Canada Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Mexico Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Mexico Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Mexico Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Germany Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Germany Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Germany Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. France Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. France Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. France Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. U.K. Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. U.K. Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. U.K. Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Italy Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Italy Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Italy Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Spain Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Spain Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Spain Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Russia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Russia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Russia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Netherlands Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Netherlands Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Netherlands Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Nordic Countries Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Nordic Countries Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Nordic Countries Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. China Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. China Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. China Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Japan Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Japan Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Japan Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. South Korea Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. South Korea Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. South Korea Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. India Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. India Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. India Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Australia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Australia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Australia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Southeast Asia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Southeast Asia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Southeast Asia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Brazil Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Brazil Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Brazil Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Argentina Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Argentina Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Argentina Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Chile Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Chile Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Chile Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Colombia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Colombia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Colombia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Peru Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Peru Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Peru Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Israel Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Israel Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Israel Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. UAE Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. UAE Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. UAE Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Turkey Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Turkey Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Turkey Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Iran Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Iran Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Iran Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Egypt Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Egypt Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Egypt Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Granulocyte Macrophage Colony Stimulating Factor Value Chain Figure 131. Manufacturing Cost Structure Figure 132. Granulocyte Macrophage Colony Stimulating Factor Sales Mode & Process Figure 133. Direct Comparison with Distribution Share Figure 134. Distributors Profiles Figure 135. Years Considered Figure 136. Research Process Figure 137. Key Executives Interviewed

Scope & coverage.

Types
  • CG-0070
  • Lenzilumab
  • Gimsilumab
  • MGN-1601
  • GSK-3196165
  • Others
Applications
  • Solid Tumor
  • Kidney Cancer
  • Lymphoma
  • Lung Disease
  • Others
Companies covered
  • Takeda Pharmaceutical Co Ltd
  • GlaxoSmithKline Plc
  • Amgen Inc
  • Sillajen Biotherapeutics
  • Morphotek Inc
  • Mologen AG
  • Humanigen Inc
  • Cold Genesys Inc
  • BriaCell Therapeutics Corp
  • Aduro BioTech Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032)
  4. 1.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume (2021-2032)
  5. 1.2.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Granulocyte Macrophage Colony Stimulating Factor Market Dynamics
  1. 2.1 Granulocyte Macrophage Colony Stimulating Factor Industry Trends
  2. 2.2 Granulocyte Macrophage Colony Stimulating Factor Industry Drivers
  3. 2.3 Granulocyte Macrophage Colony Stimulating Factor Industry Opportunities and Challenges
  4. 2.4 Granulocyte Macrophage Colony Stimulating Factor Industry Restraints
3 Granulocyte Macrophage Colony Stimulating Factor Market by Company
  1. 3.1 Global Granulocyte Macrophage Colony Stimulating Factor Company Revenue Ranking in 2025
  2. 3.2 Global Granulocyte Macrophage Colony Stimulating Factor Revenue by Company (2021-2026)
  3. 3.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Company (2021-2026)
  4. 3.4 Global Granulocyte Macrophage Colony Stimulating Factor Average Price by Company (2021-2026)
  5. 3.5 Global Granulocyte Macrophage Colony Stimulating Factor Company Ranking (2024-2026)
  6. 3.6 Global Granulocyte Macrophage Colony Stimulating Factor Company Manufacturing Base and Headquarters
  7. 3.7 Global Granulocyte Macrophage Colony Stimulating Factor Company Product Type and Application
  8. 3.8 Global Granulocyte Macrophage Colony Stimulating Factor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Granulocyte Macrophage Colony Stimulating Factor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Granulocyte Macrophage Colony Stimulating Factor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Granulocyte Macrophage Colony Stimulating Factor Market by Type
  1. 4.1 Granulocyte Macrophage Colony Stimulating Factor Type Introduction
  2. 4.1.1 CG-0070
  3. 4.1.2 Lenzilumab
  4. 4.1.3 Gimsilumab
  5. 4.1.4 MGN-1601
  6. 4.1.5 GSK-3196165
  7. 4.1.6 Others
  8. 4.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Type
  9. 4.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Type
  13. 4.3.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Type (2021-2032)
  15. 4.3.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type (2021-2032)
5 Granulocyte Macrophage Colony Stimulating Factor Market by Application
  1. 5.1 Granulocyte Macrophage Colony Stimulating Factor Application Introduction
  2. 5.1.1 Solid Tumor
  3. 5.1.2 Kidney Cancer
  4. 5.1.3 Lymphoma
  5. 5.1.4 Lung Disease
  6. 5.1.5 Others
  7. 5.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Application
  8. 5.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Application
  12. 5.3.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Application (2021-2032)
  14. 5.3.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application (2021-2032)
6 Granulocyte Macrophage Colony Stimulating Factor Regional Sales and Value Analysis
  1. 6.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region (2021-2032)
  3. 6.2.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region: 2021-2026
  4. 6.2.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Region (2027-2032)
  5. 6.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Region (2027-2032)
  9. 6.5 Global Granulocyte Macrophage Colony Stimulating Factor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032)
  12. 6.6.2 North America Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032)
  15. 6.7.2 Europe Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032)
  21. 6.9.2 South America Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Country, 2025 VS 2032
7 Granulocyte Macrophage Colony Stimulating Factor Country-level Sales and Value Analysis
  1. 7.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2032)
  4. 7.3.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2021-2026)
  5. 7.3.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales by Country (2027-2032)
  6. 7.4 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Granulocyte Macrophage Colony Stimulating Factor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Granulocyte Macrophage Colony Stimulating Factor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Granulocyte Macrophage Colony Stimulating Factor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Co Ltd
  2. 8.1.1 Takeda Pharmaceutical Co Ltd Company Information
  3. 8.1.2 Takeda Pharmaceutical Co Ltd Business Overview
  4. 8.1.3 Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Co Ltd Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Co Ltd Recent Developments
  7. 8.2 GlaxoSmithKline Plc
  8. 8.2.1 GlaxoSmithKline Plc Company Information
  9. 8.2.2 GlaxoSmithKline Plc Business Overview
  10. 8.2.3 GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Plc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  12. 8.2.5 GlaxoSmithKline Plc Recent Developments
  13. 8.3 Amgen Inc
  14. 8.3.1 Amgen Inc Company Information
  15. 8.3.2 Amgen Inc Business Overview
  16. 8.3.3 Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  18. 8.3.5 Amgen Inc Recent Developments
  19. 8.4 Sillajen Biotherapeutics
  20. 8.4.1 Sillajen Biotherapeutics Company Information
  21. 8.4.2 Sillajen Biotherapeutics Business Overview
  22. 8.4.3 Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sillajen Biotherapeutics Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  24. 8.4.5 Sillajen Biotherapeutics Recent Developments
  25. 8.5 Morphotek Inc
  26. 8.5.1 Morphotek Inc Company Information
  27. 8.5.2 Morphotek Inc Business Overview
  28. 8.5.3 Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Morphotek Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  30. 8.5.5 Morphotek Inc Recent Developments
  31. 8.6 Mologen AG
  32. 8.6.1 Mologen AG Company Information
  33. 8.6.2 Mologen AG Business Overview
  34. 8.6.3 Mologen AG Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Mologen AG Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  36. 8.6.5 Mologen AG Recent Developments
  37. 8.7 Humanigen Inc
  38. 8.7.1 Humanigen Inc Company Information
  39. 8.7.2 Humanigen Inc Business Overview
  40. 8.7.3 Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Humanigen Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  42. 8.7.5 Humanigen Inc Recent Developments
  43. 8.8 Cold Genesys Inc
  44. 8.8.1 Cold Genesys Inc Company Information
  45. 8.8.2 Cold Genesys Inc Business Overview
  46. 8.8.3 Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Cold Genesys Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  48. 8.8.5 Cold Genesys Inc Recent Developments
  49. 8.9 BriaCell Therapeutics Corp
  50. 8.9.1 BriaCell Therapeutics Corp Company Information
  51. 8.9.2 BriaCell Therapeutics Corp Business Overview
  52. 8.9.3 BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 BriaCell Therapeutics Corp Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  54. 8.9.5 BriaCell Therapeutics Corp Recent Developments
  55. 8.10 Aduro BioTech Inc
  56. 8.10.1 Aduro BioTech Inc Company Information
  57. 8.10.2 Aduro BioTech Inc Business Overview
  58. 8.10.3 Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Aduro BioTech Inc Granulocyte Macrophage Colony Stimulating Factor Product Portfolio
  60. 8.10.5 Aduro BioTech Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Granulocyte Macrophage Colony Stimulating Factor Value Chain Analysis
  2. 9.1.1 Granulocyte Macrophage Colony Stimulating Factor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Granulocyte Macrophage Colony Stimulating Factor Sales Mode & Process
  6. 9.2 Granulocyte Macrophage Colony Stimulating Factor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Granulocyte Macrophage Colony Stimulating Factor Distributors
  9. 9.2.3 Granulocyte Macrophage Colony Stimulating Factor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst